4S-AF scheme and ABC pathway guided management improves outcomes in atrial fibrillation patients

被引:29
作者
Guo, Yutao [1 ,2 ,3 ]
Imberti, Jacopo F. [2 ,3 ,4 ]
Kotalczyk, Agnieszka [2 ,3 ,5 ]
Wang, Yutang [6 ]
Lip, Gregory Y. H. [2 ,3 ,7 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Pulm Vessel & Thrombot Dis, Beijing, Peoples R China
[2] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England
[3] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[4] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Cardiol Div, Policlin Modena, Modena, Italy
[5] Med Univ Silesia, Silesian Ctr Heart Dis, Dept Cardiol Congenital Heart Dis & Electrotherap, Zabrze, Poland
[6] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 2, Dept Cardiol, Beijing, Peoples R China
[7] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
基金
北京市自然科学基金;
关键词
4S-AF scheme; ABC pathway; atrial fibrillation; guidelines; MOBILE HEALTH TECHNOLOGY; FOCUSED UPDATE; RISK-FACTOR; SOCIETY; STROKE; GUIDELINES; CARE;
D O I
10.1111/eci.13751
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The 4S-AF scheme and the ABC pathway for integrated care have been proposed to better characterize and treat patients with atrial fibrillation (AF). We aimed to evaluate the assessment of the 4S-AF scheme and ABC pathway in Chinese AF patients. Methods The ChiOTEAF is a prospective, observational, multicentre registry. Consecutive AF patients from 44 centres across 20 Chinese provinces with available 1-year follow-up data were included. Results A total of 6419 patients were included, median age 76 years (interquartile range 67-83; 39.1% female). Of these, 3503 (59.8%) patients were not characterized using the 4S-AF scheme and not management according to the ABC pathway (group 1); 1795 (28.0%) were characterized according to the 4S-AF scheme but ABC pathway non-adherent or vice versa (group 2); and 1121 (17.4%) characterized according to the 4S-AF scheme and were ABC pathway adherent (group 3). As compared with group 1, group 2 and group 3 were independently associated with lower odds of the composite endpoint of all-cause death/any thromboembolic event, with the greatest benefit observed in group 3 (OR: 0.19; 95% CI 0.12-0.31) [for group 2: OR: 0.28; 95% CI 0.20-0.37]. Similar results were observed for all-cause death (group 2: OR: 0.18; 95% CI 0.12-0.27; group 3: OR: 0.14; 95% CI 0.07-0.25). Conclusions In a contemporary real-word cohort of Chinese AF patients, it is feasible to characterize and manage AF patients using the novel 4S-AF scheme and ABC pathway for integrated care. The use of both these tools is associated with improved clinical outcomes.
引用
收藏
页数:8
相关论文
共 26 条
[1]   2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation [J].
Andrade, Jason G. ;
Verma, Atul ;
Mitchell, L. Brent ;
Parkash, Ratika ;
Leblanc, Kori ;
Atzema, Clare ;
Healey, Jeff S. ;
Bell, Alan ;
Cairns, John ;
Connolly, Stuart ;
Cox, Jafna ;
Dorian, Paul ;
Gladstone, David ;
McMurtry, M. Sean ;
Nair, Girish M. ;
Pilote, Louise ;
Sarrazin, Jean-Francois ;
Sharma, Mike ;
Skanes, Allan ;
Talajic, Mario ;
Tsang, Teresa ;
Verma, Subodh ;
Wyse, D. George ;
Nattel, Stanley ;
Macle, Laurent .
CANADIAN JOURNAL OF CARDIOLOGY, 2018, 34 (11) :1371-1392
[2]  
Camm AJ, 2012, EUR HEART J, V33
[3]  
Camm AJ, 2010, EUR HEART J, V31, P2369, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]
[4]   2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary * [J].
Chao, Tze-Fan ;
Joung, Boyoung ;
Takahashi, Yoshihide ;
Lim, Toon Wei ;
Choi, Eue-Keun ;
Chan, Yi-Hsin ;
Guo, Yutao ;
Sriratanasathavorn, Charn ;
Oh, Seil ;
Okumura, Ken ;
Lip, Gregory Y. H. .
THROMBOSIS AND HAEMOSTASIS, 2022, 122 (01) :20-47
[5]   Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor The Loire Valley Atrial Fibrillation Project [J].
Fauchier, Laurent ;
Lecoq, Coralie ;
Clementy, Nicolas ;
Bernard, Anne ;
Angoulvant, Denis ;
Ivanes, Fabrice ;
Babuty, Dominique ;
Lip, Gregory Y. H. .
CHEST, 2016, 149 (04) :960-968
[6]  
Ferreira C, 2015, ARQ BRAS CARDIOL, V105, P519
[7]   Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort [J].
Guo, Yutao ;
Guo, Jun ;
Shi, Xiangmin ;
Yao, Yuan ;
Sun, Yihong ;
Xia, Yunlong ;
Yu, Bo ;
Liu, Tong ;
Chen, Yundai ;
Lip, Gregory Y. H. .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 82 :105-111
[8]   Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation [J].
Guo, Yutao ;
Lane, Deirdre A. ;
Wang, Limin ;
Zhang, Hui ;
Wang, Hao ;
Zhang, Wei ;
Wen, Jing ;
Xing, Yunli ;
Wu, Fang ;
Xia, Yunlong ;
Liu, Tong ;
Wu, Fan ;
Liang, Zhaoguang ;
Liu, Fan ;
Zhao, Yujie ;
Li, Rong ;
Li, Xin ;
Zhang, Lili ;
Guo, Jun ;
Burnside, Girvan ;
Chen, Yundai ;
Lip, Gregory Y. H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (13) :1523-1534
[9]   Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study [J].
Guo, Yutao ;
Wang, Yutang ;
Li, Xiaoying ;
Shan, Zaoliang ;
Shi, Xiangmin ;
Xi, Guorong ;
Lip, Gregory Y. H. .
BMJ OPEN, 2018, 8 (05)
[10]  
Hindricks G, 2021, EUR HEART J, V42, P546, DOI [10.1093/eurheartj/ehaa945, 10.1093/eurheartj/ehaa612]